All 16 peptides were commercially synthesised by Mimotopes (Mulgrave Victoria, Australia) via solid phase Fmoc synthesis method . All the synthetic peptides were purified by reversephase high performance liquid chromatography (RP-HPLC) to >95% purity and characterised by mass spectrometry. The design of the peptides was based on the native templates of human betadefensins (HBD)-1 to -3 and human cathelicidin (LL-37), which are important components of AMPs.